Evidence from both experimental models and clinical studies indicates that selective inhibition of PKC-β with Ruboxistaurin (RBX) effectively restores vascular reactivity and mitigates hyperglycemia-induced endothelial dysfunction [52, 53]. Here, PRKCB is linked to Hyperglycemia.